Table 1.
Baseline characteristics for patients with a decrease in HDL-C (≥0.1 mmol/L), an increase in HDL-C (≥0.1 mmol/L), or no change in HDL-C (±0.1 mmol/L) (unmatched and propensity score-matched populations)
| Variable | Unmatched population | Propensity score-matched population | ||||
|---|---|---|---|---|---|---|
| Decreased (n = 3068) | Unchanged (n = 8919) | Increased (n = 3370) | Decreased (n = 2975) | Unchanged (n = 2975) | p valuea | |
| Women, n (%) | 1872 (61.0) | 4840 (54.3) | 1997 (59.3) | 1803 (60.6) | 1798 (60.4) | 0.92 |
| Age (years) | 62.3 (10.2) | 62.6 (10.2) | 63.0 (9.8) | 62.2 (10.1) | 62.3 (10.2) | 0.64 |
| Simvastatin, n (%) | 2925 (95.3) | 8510 (95.4) | 3244 (96.3) | 2835 (95.3) | 2823 (94.9) | 0.09 |
| Dose (mg) | 20.8 (9.7) | 19.7 (8.7) | 20.2 (8.8) | 20.8 (9.7) | 19.7 (8.4) | <0.01 |
| Hospitalisations, number/year prior to statin start | 0.2 (0.6) | 0.2 (0.6) | 0.19 (0.6) | 0.2 (0.6) | 0.2 (0.6) | 0.16 |
| Systolic blood pressure (mmHg) | 144.6 (19.8) | 143.6 (18.6) | 144.0 (18.9) | 144.6 (19.8) | 143.3 (19.0) | 0.02 |
| Diastolic blood pressure (mmHg) | 82.6 (10.4) | 82.0 (10.1) | 82.0 (10.4) | 82.7 (10.4) | 81.9 (10.2) | 0.01 |
| Body mass index (kg/cm2) | 28.6 (5.0) | 29.4 (5.0) | 28.8 (4.9) | 28.7 (5.0) | 28.6 (5.2) | 0.67 |
| HbA1c (%) | 5.5 (1.3) | 5.7 (1.3) | 5.64 (1.4) | 5.6 (1.3) | 5.6 (1.4) | 0.77 |
| HDL-C (mol/L) | 1.69 (0.47) | 1.41 (0.40) | 1.44 (0.42) | 1.66 (0.43) | 1.66 (0.45) | 0.95 |
| LDL-C (mmol/L) | 4.53 (1.00) | 4.45 (0.95) | 4.52 (0.97) | 4.53 (0.99) | 4.52 (0.96) | 0.71 |
| Change in LDL-C (mmol/L) | −1.96 (0.81) | −1.84 (0.70) | −1.86 (0.75) | −1.95 (0.80) | −1.96 (0.73) | 0.92 |
| Total cholesterol (mmol/L) | 6.88 (1.10) | 6.66 (1.04) | 6.77 (1.07) | 6.86 (1.09) | 6.86 (1.05) | 0.86 |
| Triglycerides (mmol/L) | 1.61 (0.45) | 1.37 (0.38) | 1.40 (0.40) | 1.53 (0.75) | 1.55 (0.75) | 0.23 |
| Antihypertensives (hypertension), n (%) | 1426 (46.5) | 4320 (48.4) | 1530 (45.4) | 1379 (46.4) | 1410 (47.4) | 0.44 |
| Diabetes, n (%) | 691 (22.5) | 2433 (27.3) | 834 (24.8) | 678 (22.8) | 680 (22.9) | 0.98 |
| Myocardial infarction, n (%) | 107 (3.5) | 254 (2.9) | 81 (2.4) | 93 (3.1) | 93 (3.1) | 1.00 |
| Unstable angina pectoris, n (%) | 45 (1.5) | 129 (1.5) | 46 (1.4) | 44 (1.5) | 43 (1.5) | 1.00 |
| Heart failure, n (%) | 75 (2.4) | 237 (2.7) | 75 (2.2) | 73 (2.5) | 72 (2.4) | 1.00 |
| Arrhythmia, n (%) | 182 (5.9) | 480 (5.4) | 175 (5.2) | 177 (6.0) | 180 (6.1) | 0.64 |
| Peripheral arterial disease, n (%) | 54 (1.8) | 130 (1.5) | 56 (1.7) | 52 (1.8) | 44 (1.5) | 0.47 |
| Cerebrovascular disease, n (%) | 242 (7.9) | 665 (7.5) | 208 (6.2) | 181 (6.1) | 172 (5.8) | 0.66 |
Values are expressed as mean (SD) unless specified otherwise
HbA1c glycated haemoglobin, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol
a T test for continuous variables and Chi-square test for categorical variable